Division of Experimental Oncology

2005-2008

2008 | 2007 | 2006 | 2005
 

2008

Derré L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A, Zoete V, Romero P, Michielin O, Speiser DE, and Rufer N. Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc. Natl. Acad. U.S.A. 105(39):1510-15015. 2008  PubMed

Voelter V, Rufer N, Reynard S, Greub G, Brookes R, Guillaume P, Grosjean F, Fagerberg T, Michielin O, Rowland-Jones S, Pinilla C, Leyvraz S, Romero, P, and Appay V. Characterization of Melan-A reactive memory CD8+ T-cells in a healthy donor. Int Immunol. 20:1087-1096. 2008  PubMed

Voelter V, Pica A, Laurent J, Rimoldi D, Bouzourene H, Sajadi A, Matter M, Romero P, Rufer N, and Speiser DE. An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy-with late immune escape in the brain. Cancer Immun. 8:6-9. 2008  PubMed

Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Romero P, and Rufer N. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. U.S.A. 105(10):3849-54. 2008  PubMed

Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D, Gaide O, Guzzardi M, Iancu EM, Rufer N, Fasel N, and Thome M. The proteolytic activity of Malt1 plays a key role in T-cell activation. Nature Immunol. 9(3):272-81. 2008  PubMed

Iancu EM, Speiser DE, and Rufer N. Assessing ageing of individual T lymphocytes: Mission impossible? Mech Ageing Dev. 129(1-2):67-78. 2008  PubMed

 

TOP ^

2007

Appay V, Bosio A, Lokan S, Wiencek Y, Biervert C, Kusters D, Devevre E, Speiser DE, Romero P, Rufer N, and Leyvraz S. Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. J Immunol. 179(11):7406-14. 2007  PubMed 

Derré L, Bruyninx M, Baumgaertner P, Devevre E, Corthesy P, Touvrey C, Mahnke YD, Pircher H, Voelter V, Romero P, Speiser DE, and Rufer N. In vivo persistence of co-dominant human CD8+ T-cell clonotypes is not limited by replicative senescence or functional alteration. J Immunol. 179(4):2368-79. 2007  PubMed

Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II, Rufer N, Romero P, Morgan RA, Schumacher TN, Haanen JB. Selecting highly affine and well expressed TCRs for gene therapy of melanoma. Blood. 110(10):3564-72. 2007  PubMed

Appay V, Voelter V, Rufer N, Reynard S, Gasparini D, Liénard D, Speiser DE, Schneider P, Cerottini JC, Romero P, and Leyvraz S. Combination of transient lymphodepletion with Busulfan and Fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother. 30(2):240-50. 2007  PubMed

Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, Corthesy P, Devevre E, Speiser DE, and Rufer N. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol. 178(7):4112-19. 2007  PubMed

Barbey C, Baumgaertner P, Devevre E, Rubio-Godoy V, Derre L, Bricard G, Guillaume P, Luescher IF, Liénard D, Cerottini J-C, Romero P, Speiser DE and Rufer N. IL-12 controls cytotoxicity of a novel subset of self antigen-specific human CD28+ cytolytic T-cells. J Immunol. 178(6):3566-74. 2007  PubMed

Thadikkaran L, Menzel O, Tissot J-D, and Rufer N. Proteomic and transcriptomic analysis of human CD8+ T lymphocytes over-expressing telomerases. Proteomics Clin. Appl. 1:299-311. 2007 

 

TOP ^

2006

Tabiasco J, Devevre E, Rufer N, Salaun B, Cerottini J-C, Speiser DE, and Romero P. Human effector CD8+ T lymphocytes express toll like receptor-3 as a functional coreceptor. J Immunol. 177(12):8708-13. 2006  PubMed 

Menzel O, Migliaccio M, Goldstein DR, Dahoun S, Delorenzi M, and Rufer N. Mechanisms regulating the proliferative potential of human CD8+ T lymphocytes over-expressing telomerase. J Immunol. 177(6):3657-68. 2006  PubMed

Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Liénard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N and Speiser DE. New generation vaccine induces effective melanoma specific CD8+ T-cells in the circulation but not in the tumor site. J Immunol. 177(3):1670-78. 2006  PubMed

Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Corthesy P, Devevre E, Dietrich PY, Liénard D, Cerottini JC, Romero P and Rufer N. A novel approach to characterize clonality and differentiation of human melanoma-specific T-cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol. 177(2):1338-48. 2006  PubMed

Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S, Pinilla C and Romero P. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur J Immunol. 36(7):1805-14. 2006  PubMed

Colombetti S, Fagerberg T, Baumgaertner P, Chapatte L, Speiser DE, Rufer N, Michielin O and Lévy, F. Impact of orthologous Melan-A peptide vaccination on the anti-self Melan-A/HLA-A2 T cell cross-reactivity. J Immunol. 176(11):6560-7. 2006  PubMed

Bianchi T, Rufer N, MacDonald HR and Migliaccio M. The tumor suppressor p16(Ink4a) regulates T lymphocyte survival. Oncogene. 25(29):4110-5. 2006  PubMed

Baumgaertner P, Rufer N, Devêvre E, Derré L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P and Speiser DE. Ex vivo detectable human CD8 T cell responses to Cancer-Testis antigens. Cancer Res. 66(4): 1912-6. 2006  PubMed

Migliaccio M, Alves PM, Romero P and Rufer N. Distinct mechanisms control human naive and antigen-experienced CD8+ T lymphocyte proliferation. J Immunol. 176(4):2173-82. 2006  PubMed

 

TOP ^

2005

Montes M, Rufer N, Appay V, Reynard S, Pittet MJ, Speiser DE, Guillaume P, Cerottini JC, Romero P and Leyvraz S. Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin Exp Immunol. 142(2), 292-302. 2005  PubMed

Rufer N. Molecular tracking of antigen-specific T-cell clones during immune responses. Curr Opin Immunol. 17(4);441-7. 2005  PubMed

Migliaccio M, Raj K, Menzel O and Rufer N. Mechanisms that limit the in vitro proliferative potential of human CD8+ T lymphocytes. J Immunol. 174(6):3335-43. 2005  PubMed

Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini J-C and Romero P. Addition of CpG oligodeoxynucleotide 7909 to peptide-based vaccines dramatically improves human CD8+ T-cell responses in vivo. J Clin Invest. 115(3):739-46. 2005  PubMed

Rufer N, Reichenbach P and Romero P. Methods for the ex-vivo characterization of human CD8+ T subsets based on gene expression and replicative history analysis. Methods Mol Med. 109;265-84. 2005  PubMed

 

TOP ^

Search:
 inside this site:
   
   
 Go
 
rss/atom
Chemin des Boveresses 155 - CH-1066 Epalinges  - Switzerland  -  Tel. +41 21 69258 42  -  Fax +41 21 65269 33
Swiss University